The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

However, some research suggests that poor sleep could raise your risk of Alzheimer’s. A study published in November found ...

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...

Delays in dreaming might be an early warning sign of Alzheimer's disease. People who take significantly longer to enter the ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.